Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
Accessnewswireยท2025-11-17 20:40
ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it has completed the initial stage of a strategic realignment by acquiring a controlling interest in LAMY, an SEC-reporting company (OTCID:LMMY), in exchange for Exousia Pro's subsidiary, Exousia AI, Inc., in an all-stock transaction. Exousia Pro received approximately 51% of LMMY restricted Common Stock, positioni ...